We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly upped its guidance for 2019 after posting strong third quarter results, as more recently released drugs offset sales lost as erectile dysfunction blockbuster Cialis lost patent protection.

Eli Lilly has suffered a major setback after the US regulator rejected its rheumatoid arthritis pill, baricitinib, sending the company’s share price plummeting. Lilly received a letter from the ...

said it believed the pill could cause fewer side effects than injectable treatments from Novo Nordisk and Eli Lilly. Patients ...

When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for its experimental obesity pill ... similar to Eli Lilly's (LLY ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...